BioSpace News Archive

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) today announced that the Company recently enrolled the first subject in its Phase 2 SEISMiC Extension Study of istaroxime in the treatment of early cardiogenic shock.

Notable Labs, Ltd. and CicloMed, LLC announced initial safety and efficacy data of fosciclopirox and the performance of PPMP, Notable’s Predictive Precision Medicines Platform, from the Phase 2a trial in adult patients with relapsed/refractory acute myeloid leukemia, R/R AML.

RNAimmune, Inc., a partner of Innoforce, announced the U.S. Food and Drug Administration (FDA) granted IND clearance for its RV-1770 Respiratory Syncytial Virus (RSV) mRNA vaccine.

Twist Bioscience Corporation today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 5:15 p.m. Pacific Time.

The first patient has been dosed in two global, randomized phase 3 trials evaluating the efficacy and safety of Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in combination with durvalumab, AstraZeneca’s anti-PD-L1 therapy, in two types of breast cancer.

Spectrum Solutions® and its owned corporations, Alimetrix, Inc., and Microarrays, Inc., announced the appointment of Bill Phillips as the company’s new chief executive officer, replacing Stephen J. Fanning, who successfully served as Spectrum’s CEO for over four years.

Edgewise Therapeutics, Inc. today announced the launch of an educational website dedicated to the Becker muscular dystrophy (Becker) community.

Bausch Health, Canada today announced that DUOBRII is now available to patients enrolled in Quebec’s public drug plan operated by the Régie de l’assurance maladie du Québec (RAMQ).

Laxxon Medical today announced that management is scheduled to participate in the 26th Annual Needham Growth Conference on January 17th and 18th, 2024 in New York City.

Panbela Therapeutics, Inc. (Nasdaq: PBLA) today announced that US WorldMeds®1 (USWM), a Kentucky-based specialty pharmaceutical company to whom it divested certain assets in its eflornithine pediatric neuroblastoma program, received FDA approval of its New Drug Application (NDA) for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients who have achieved at least a partial response to certain prior therapies.